CNIPA.AI
검색으로 돌아가기
기록

ENGINEERED IMMUNE CELLS WITH ENHANCED POTENCY AND USES OF SAME IN IMMUNOTHERAPY

발명심사 중
2조회수
21청구항 · 5 독립항
§ Ⅰ

개요

발명자

James Barnaby Trager; Ivan Chan; Don-Hong Wang; Guangnan Li; Alexandra Leida Liana Lazetic; Chao Guo

IPC 분류

A61K 40/31A61K 40/11A61K 40/15A61K 40/42C7K 14/725C7K 16/30

CPC 분류

A61K40/31A61K40/11A61K40/15A61K40/42C7K14/7051C7K16/30

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors as well as genetically edited or otherwise engineered enhance the persistence the cells in immunotherapy. In several embodiments, the cells are edited to knock out a target gene that encodes a protein involved in antigen processing and presentation by major histocompatibility complex class I molecules. In several embodiments, a mixture of immune cell types is used, optionally in allogeneic therapy. The engineering and editing of the cells, such as NK cells and/or T cells exhibit enhanced cytotoxicity and/or persistence, as well as reduced risk of reduced graft versus host, host versus graft, and graft versus graft effects.

원문 (중국어)

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors as well as genetically edited or otherwise engineered enhance the persistence the cells in immunotherapy. In several embodiments, the cells are edited to knock out a target gene that encodes a protein involved in antigen processing and presentation by major histocompatibility complex class I molecules. In several embodiments, a mixture of immune cell types is used, optionally in allogeneic therapy. The engineering and editing of the cells, such as NK cells and/or T cells exhibit enhanced cytotoxicity and/or persistence, as well as reduced risk of reduced graft versus host, host versus graft, and graft versus graft effects.